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Abstract 
Purpose: To report a first case of bullous pemphigoid (BP) following intravenous 
fluorescein for fundus angiography.  
Clinical Features: A 70-year-old male patient was admitted to the intensive care unit 
with BP and sepsis. He reported a history of fundus fluorescein angiography with a pre-
diagnosis of senile macular degeneration 2 months prior to presentation. At that time, 
fluorescein extravasated at the antecubital region. Following the procedure, pruritus and 
erythema began at the wrists bilaterally, and quickly spread to the entire body. The 
patient also reported a history of allergy to human albumin solution (Plamasteril; 
Abbott) 15 years before, during bypass surgery. On dermatologic examination, 
erythematous patches were present on the scalp, chest and anogenital region. Vesicles 
and bullous lesions were present on upper and lower extremities. On day 2 of 
hospitalization, tense bullae appeared on the upper and lower extremities. The patient 
was treated with oral methylprednisolone 48 mg (Prednol; Mustafa Nevzat), topical 
clobetasol dipropionate 0.05% cream (Dermovate; Glaxo SmithKline), and topical 4% 
urea lotion (Excipial Lipo; Orva) for presumptive bullous pemphigoid. Skin punch 
biopsy provided tissue for histopathology, direct immunofluorescence examination, and 
salt extraction, which were all consistent with BP. After 1 month, the patient was 
transferred to the intensive care unit with sepsis secondary to urinary tract infection; he 
died 2 weeks later from sepsis and cardiac failure.  
Conclusions: To our knowledge, this is the first reported case of BP following fundus 
fluorescein angiography in a patient with known human albumin solution allergy. 
Consideration should be made to avoid fluorescein angiography, change administration 
route, or premedicate with antihistamines in patients with known human albumin 
solution allergy. The association between fundus fluorescein angiography and BP should 
be further investigated.  
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Bullous pemphigoid (BP) is the most common subepidermal autoimmune blistering 
disease. It is characterized histologically by subepidermal blisters and 
immunopathologically by deposition of autoantibodies and complement components 
along the epidermal basement membrane [1]. Most patients have circulating 
autoantibodies directed against two proteins: a 230 kDa hemidesmosome component and 
a 180 kDa lamina lucida component, both from the dermoepidermal junction [1, 2]. BP 
typically affects persons after the seventh decade of life. The annual incidence is estimated 
at 6 to 30 per one million population. Recent higher estimates of BP rates may be related 
to improved diagnosis using modern laboratory techniques. So far, there is no indication 
for a geographic predilection of the disease [3]. 
Case Report 
A 70-year-old male patient was admitted to the intensive care unit (ICU) with BP and sepsis. The 
patient’s history was significant for fundus fluorescein angiography (FFA) 2 months prior to diagnosis 
of senile macular degeneration. The procedure was complicated by fluorescein extravasation at the 
antecubital region. At that time, the patient experienced pruritus and erythema that began at the wrists 
and spread quickly to cover the entire body. His past medical history was significant for essential 
hypertension, glaucoma, and senile macular degeneration. His medications included oral metoprolol 50 
mg (Beloc), oral aspirin 100 mg (Coraspin), and brimonidine tartrate 0.2% (Alphagan) ophthalmic 
solution. The patient also reported a history of allergy to human albumin solution (Plamasteril; 
Abbott), which he had received during bypass surgery 15 years before. 
On dermatological examination, erythematous patches were present on the scalp, chest and 
anogenital region. Vesicles and tense bullae were present on all extremities (fig. 1). The patient was 
treated for presumed BP with daily oral methylprednisolone 48 mg, topical clobetasol dipropionate 
0.05% cream (Dermovate; Glaxo SmithKline), and topical 4% urea lotion (Excipial Lipo; Orva). 
A complete blood count revealed relative eosinophilia. Punch biopsies were performed of the 
affected area. Histopathologic examination revealed subepidermal blistering and dermal infiltrates of 
mononuclear cells and eosinophils. Focal areas of collagen flame figures were also noted. The dermal-
epidermal junction showed direct immunofluorescence linear reactivity for C3c and IgG. Salt extraction 
testing was consistent with BP. 
Regression of the lesions began at day 6, at which time daily oral azathioprine 150 mg (Imuran) was 
added. Following resolution of all lesions, the patient was discharged with prescriptions for oral 
methylprednisolone 40 mg, topical 4% urea lotion (Excipial Lipo; Orva) and oral azathioprine 
(Imuran) 150 mg daily. One month later, he was admitted to the ICU with sepsis secondary to urinary 
tract infection due to underlying decreased immune response. He died in the ICU from cardiac failure 2 
weeks later. 
Discussion 
There has been considerable progress in understanding the physiopathology of BP 
during the past two decades. Nevertheless, BP frequently presents a diagnostic and 
therapeutic challenge. Several cases of BP in patients with diabetes mellitus, inflammatory 
bowel disease, rheumatoid arthritis, Hashimoto’s thyroiditis, dermatomyositis, lupus 
erythematosus, myasthenia gravis and autoimmune thrombocytopenia have been 
reported [3, 4]. 
Although medications have been implicated in the development of BP [5], the 
mechanisms by which drugs can cause BP are unclear. One hypothesis is that drugs may 
trigger BP in patients with underlying genetic susceptibility, either by modifying the 
immune response or by altering the antigenic properties of the epidermal basement 
membrane [1]. A case control study assessing long-term drug use and development of BP  
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showed that diuretics (particularly aldosterone antagonists) and neuroleptics were used 
more frequently by BP patients than control patients [1]. Because of these associations, 
potential drug causes should be considered in all BP patients.  
Fluorescein angiography is a relatively safe procedure, with a risk profile comparable to 
that of other intravenous radiocontrast media angiography [6, 7]. Sodium fluorescein is a 
low-molecular-weight, highly water-soluble compound with fluorescent properties. 
Because of the physical properties of fluorescein, it is routinely used for medical and laser 
treatment of chorioretinal diseases. The pathogenic and immune mechanisms that cause 
adverse reactions in 5% of patients receiving intravenous fluorescein are unknown. 
Adverse drug reactions to fluorescein are classified as mild, moderate, severe, and fatal 
[6]. Severe adverse reactions (0.05%) include cardiovascular shock, myocardial infarction, 
laryngeal edema, and bronchospasm, and require prolonged, intensive care [7]. 
This patient had a history of allergy to a colloidal plasma substitute. These substitutes 
produce early and late allergic reactions due to starch components. Patients with a 
previous reaction to colloidal plasma substitute have a 48% incidence of adverse events 
with subsequent tests. Although these rates are obviously high, we have no recent studies 
about the present rates [8, 9]. 
Adverse reactions following intravenous fluorescein are very unusual, but a history of 
dye allergy, diabetes, or systemic arterial hypertension increases the risk of allergic 
reaction to fluorescein [6–8]. Prophylactic treatment, fluorescein desensitization or oral 
fluorescein angiography should be considered for high-risk patients [10]. Providers 
should be prepared to manage potential serious adverse reactions. Other imaging 
techniques, like optical coherence tomography, should be considered as an alternative in 
selected cases. To our knowledge, this is the first reported case of fluorescein-induced BP 
in a patient with colloidal plasma substitute allergy. The association between fundus 
fluorescein angiography and BP should be further investigated with a formal 
epidemiologic study. 
 
 
 
 
 
Fig. 1. Photo of erythematous target-like lesions on the wrist of the patient. 
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